{
    "doi": "https://doi.org/10.1182/blood.V124.21.2108.2108",
    "article_title": "Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens ",
    "article_date": "December 6, 2014",
    "session_type": "653. Myeloma: Therapy, excluding Transplantation: Poster I",
    "abstract_text": "Background : Autologous stem-cell transplantation (ASCT) is the standard of care for younger patients with multiple myeloma (MM). The degree of tumor reduction after ASCT is the crucial factor associated with a prolonged PFS and OS, being the M-protein decrease at the time of transplant the most important predictor of residual disease after ASCT. While there is an agreement that bortezomib and dexamethasone associated to a third drug is the induction of choice, which should be the third drug (thalidomide, lenalidomide, doxorubicin or cyclophosphamide) and the optimal number of cycles remain unknown. The results of phase 3 PETHEMA study GEM05menos65 showing a CR rate of 35% increasing overtime during the 6 induction cycles of VTD (Rosi\u00f1ol et al, Blood 2012) prompted us to study the kinetics of response to VTD and TD in this study and in similar historic data with the VD regimen in phase 2 PETHEMA VELCA/DEXA trial (Rosi\u00f1ol et al, JCO 2007). Objective : To study the kinetics of response by cycle during the 6 cycles of induction with VTD, TD and VD using a random effects model methodology. Patients and Methods : In GEM05menos65 study patients were randomized to receive 6 induction cycles of either VTD or TD followed by ASCT. One hundred and thirteen patients were treated with TD (thalidomide 200 mg daily; dexamethasone 40 mg on days 1-4 and 9-12) and 122 with VTD (TD at identical doses plus bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11) (Rosi\u00f1ol et al, Blood 2012) and had complete data set for this analysis. In VELCA/DEXA study 40 patients received 6 induction cycles of bortezomib and dexamethasone on an alternating basis (Rosi\u00f1ol et al, JCO 2007). Linear random effects models were employed to analyze the tumor response kinetics using the absolute decrease value of the serum M-protein after each cycle. Because the nonlinearity in the change of the M-protein overtime, a piecewise linear model was used to estimate mean changes in M-protein in each of the 6 cycles. Results : Three different comparisons were made: 1) the decrease of the M-protein by cycle within each treatment group, 2) the total M-protein decrease at the end of induction with VTD compared to TD and VD and 3) the decrease by cycle comparing VTD vs TD and VTD vs VD. Concerning the M-protein decrease by cycle within each arm, statistically significant decreases versus the previous cycle were observed in the first 5 cycles of VTD, the first 3 of TD and the first 4 of VD. The serum M-protein reduction at the end of the 6 induction cycles was significantly higher with VTD when compared with TD (p<0.0001) and VD (p<0.0001). Finally, when comparing the serum M-protein decrease between VTD and TD by cycle, the M-protein reduction was significantly higher with VTD in the first 5 cycles and the same analysis between VTD and VD showed that the serum M-protein decrease was significantly higher with VTD in the first 3 cycles (Tables 1 and 2). Conclusions : In the cycle by cycle analysis VTD continued to improve M-protein reduction significantly in the first 5 cycles. When compared with TD and VD, the M-protein decrease at the end of induction was significantly higher with VTD. Furthermore, in the cycle by cycle comparison there was a significantly higher efficacy of VTD over TD in the first 5 cycles and over VD in the first 3 cycles. Our results suggest a synergistic rather than only an additive effect between thalidomide and bortezomib supporting the use of an IMiD as the drug of choice to be combined with bortezomib and dexamethasone. Finally, our study supports an induction period beyond 3 or 4 cycles when using a bortezomib/IMiD regimen in order to maximize the induction efficacy. Table 1. Comparison between VTD versus TD by cycles overtime.  Serum M-protein (g/dl) Change (VTH-TH) . Estimate . SE . 95% CI . P-value . C1 \u2013 Baseline -3.0747 0.3461 (-3.7539, -2.3954) <.0001 C2 \u2013 C1 -1.1343 0.1294 (-1.3883, -0.8802) <.0001 C3 \u2013 C2 -0.4474 0.09586 (-0.6356, -0.2593) <.0001 C4 \u2013 C3 -0.2140 0.08224 (-0.3753, -0.05257) 0.0094 C5 \u2013 C4 -0.1339 0.07550 (-0.2821, -0.01428) 0.0765 C6 \u2013 C5 0.01862 0.05395 (-0.08725, 0.1245) 0.7300 Serum M-protein (g/dl) Change (VTH-TH) . Estimate . SE . 95% CI . P-value . C1 \u2013 Baseline -3.0747 0.3461 (-3.7539, -2.3954) <.0001 C2 \u2013 C1 -1.1343 0.1294 (-1.3883, -0.8802) <.0001 C3 \u2013 C2 -0.4474 0.09586 (-0.6356, -0.2593) <.0001 C4 \u2013 C3 -0.2140 0.08224 (-0.3753, -0.05257) 0.0094 C5 \u2013 C4 -0.1339 0.07550 (-0.2821, -0.01428) 0.0765 C6 \u2013 C5 0.01862 0.05395 (-0.08725, 0.1245) 0.7300 View Large Table 2. Comparison between VTD versus VD by cycles overtime.  Serum M-protein (g/dl) Change (VTH-VD) . Estimate . SE . 95% CI . P-value . C1 \u2013 Baseline -3.1553 0.2243 (-3.5957, -2.7150) <.0001 C2 \u2013 C1 -1.3748 0.2279 (-1.8223, -0.9272) <.0001 C3 \u2013 C2 -0.4266 0.2354 (-0.8887, 0.03552) 0.0703 C4 \u2013 C3 -0.05473 0.2439 (-0.5337, 0.4242) 0.8225 C5 \u2013 C4 -0.02217 0.2530 (-0.5189, 0.4745) 0.9302 C6 \u2013 C5 0.06493 0.2908 (-0.5060, 0.6358) 0.8234 Serum M-protein (g/dl) Change (VTH-VD) . Estimate . SE . 95% CI . P-value . C1 \u2013 Baseline -3.1553 0.2243 (-3.5957, -2.7150) <.0001 C2 \u2013 C1 -1.3748 0.2279 (-1.8223, -0.9272) <.0001 C3 \u2013 C2 -0.4266 0.2354 (-0.8887, 0.03552) 0.0703 C4 \u2013 C3 -0.05473 0.2439 (-0.5337, 0.4242) 0.8225 C5 \u2013 C4 -0.02217 0.2530 (-0.5189, 0.4745) 0.9302 C6 \u2013 C5 0.06493 0.2908 (-0.5060, 0.6358) 0.8234 View Large Disclosures Rosi\u00f1ol: Janssen: Honoraria; Celgene: Honoraria. Oriol: Janssen: Honoraria; Celgene: Honoraria. De La Rubia: Janssen: Honoraria; Celgene: Honoraria. Gutierrez: Janssen: Honoraria; Celgene: Honoraria. Mateos: Janssen: Honoraria; Celgene: Honoraria. Martinez-Lopez: Janssen: Honoraria; Celgene: Honoraria. Alegre: Janssen: Honoraria; Celgene: Honoraria. Feng: Janssen: Employment. van de Velde: Janssen: Employment. Lahuerta: Janssen: Honoraria; Celgene: Honoraria. San Miguel: Janssen: Honoraria; Celgene: Honoraria. Blade: Janssen: Honoraria; Celgene: Honoraria.",
    "topics": [
        "bortezomib",
        "dexamethasone",
        "kinetics",
        "multiple myeloma",
        "thalidomide",
        "autologous stem cell transplant",
        "neoplasms",
        "cyclophosphamide",
        "doxorubicin",
        "lenalidomide"
    ],
    "author_names": [
        "Laura Rosi\u00f1ol, MD PhD",
        "Albert Oriol, MD",
        "Ana Isabel Teruel",
        "Dolores Hern\u00e1ndez",
        "M Jes\u00fas Blanchard",
        "Javier De La Rubia",
        "Miquel Granell, MD",
        "Juan Besalduch",
        "Luis Palomera",
        "Yolanda Gonzalez",
        "Etxebeste M\u00aa Asunci\u00f3n",
        "Joaqu\u00edn D\u00edaz-Mediavilla",
        "Miguel T. Hernandez",
        "Felipe de Arriba",
        "Norma Carmen Gutierrez, PhD MD",
        "Maria-Victoria Mateos, MD PhD",
        "Joaquin Martinez-Lopez, MD PhD",
        "Adrian Alegre, MD",
        "Huaibao Feng",
        "Helgi van de Velde",
        "Juan Jos\u00e9 Lahuerta, MD PhD",
        "Jesus F. San Miguel",
        "Joan Blade"
    ],
    "author_dict_list": [
        {
            "author_name": "Laura Rosi\u00f1ol, MD PhD",
            "author_affiliations": [
                "Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic, Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Albert Oriol, MD",
            "author_affiliations": [
                "Hospital Germans Trias i Pujol, Barcelona, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana Isabel Teruel",
            "author_affiliations": [
                "Hospital Cl\u00ednico, Valencia, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dolores Hern\u00e1ndez",
            "author_affiliations": [
                "Hospital La Paz, Madrid, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "M Jes\u00fas Blanchard",
            "author_affiliations": [
                "Hospital Ram\u00f3n y Cajal, Madrid, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Javier De La Rubia",
            "author_affiliations": [
                "Hospital Universitario La Fe, Valencia, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miquel Granell, MD",
            "author_affiliations": [
                "Hospital Sant Pau, Barcelona, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Besalduch",
            "author_affiliations": [
                "Hospital Son Espases, Palma de Mallorca, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luis Palomera",
            "author_affiliations": [
                "Hospital Lozano Blesa, Zaragoza, Spain "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yolanda Gonzalez",
            "author_affiliations": [
                "ICO Dr Josep Trueta, Girona, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Etxebeste M\u00aa Asunci\u00f3n",
            "author_affiliations": [
                "Hospital de Donostia, Donostia, Spain "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joaqu\u00edn D\u00edaz-Mediavilla",
            "author_affiliations": [
                "Hospital Clinico de Madrid, Madrid, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel T. Hernandez",
            "author_affiliations": [
                "Hospital Universitario de Canarias, Tenerife, Spain "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Felipe de Arriba",
            "author_affiliations": [
                "Hospital Morales Messeguer, Murcia, Spain "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Norma Carmen Gutierrez, PhD MD",
            "author_affiliations": [
                "Hospital Universitario de Salamanca, Salamanca, Spain "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria-Victoria Mateos, MD PhD",
            "author_affiliations": [
                "University Hospital (IBSAL) & Cancer Research Center (IBMCC-CSIC), Salamanca, Spain "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joaquin Martinez-Lopez, MD PhD",
            "author_affiliations": [
                "Hospital Universitario 12 de Octubre, Madrid, Spain "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Adrian Alegre, MD",
            "author_affiliations": [
                "Hospital Universitario del la Princesa, Madrid, Spain "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Huaibao Feng",
            "author_affiliations": [
                "Janssen Research&Development, Raritan, NJ "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Helgi van de Velde",
            "author_affiliations": [
                "Janssen Research&Development, Janssen Pharmaceutica NV, Beerse, Belgium "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Jos\u00e9 Lahuerta, MD PhD",
            "author_affiliations": [
                "Hospital Universitario 12 de Octubre, Madrid, Spain "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jesus F. San Miguel",
            "author_affiliations": [
                "Cl\u00ednica Universidad de Navarra, Pamplona, Spain "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joan Blade",
            "author_affiliations": [
                "Hospital Clinic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-29T15:42:07",
    "is_scraped": "1"
}